Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer

PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide, an androgen receptor antagonist, in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. The trial showed that the median metastasis-free survival was 21.9 mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhea, Logan P, Gupta, Brinda, Aragon-Ching, Jeanny B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413545/
https://www.ncbi.nlm.nih.gov/pubmed/30460933
http://dx.doi.org/10.4103/aja.aja_88_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413545/
https://www.ncbi.nlm.nih.gov/pubmed/30460933
http://dx.doi.org/10.4103/aja.aja_88_18

Ejemplares similares